8TK4

HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) complexed with phosphate

Summary for 8TK4

• Entry DOI: 10.2210/pdb8tk4/pdb
• Descriptor: Dual specificity protein phosphatase 3, PHOSPHATE ION (3 entities in total)
• Functional Keywords: protein dual-specificity phosphatase, vhr, hydrolase
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 1
• Total formula weight: 20377.97

Authors

Aleshin, A.E.,Wu, J.,Lambert, L.J.,Cosford, N.D.P.,Tautz, L. (deposition date: 2023-07-25, release date: 2024-08-14, Last modification date: 2025-02-26)

Primary citation

Wu, J.,Baranowski, M.R.,Aleshin, A.E.,Isiorho, E.A.,Lambert, L.J.,De Backer, L.J.S.,Han, Y.N.,Das, R.,Sheffler, D.J.,Bobkov, A.A.,Lemberikman, A.M.,Keedy, D.A.,Cosford, N.D.P.,Tautz, L.
Fragment Screening Identifies Novel Allosteric Binders and Binding Sites in the VHR ( DUSP3 ) Phosphatase.
Acs Omega, 10:4912-4926, 2025

PubMed Abstract: The human H1-related phosphatase (VHR; ) is a critical positive regulator of the innate immune response. Recent studies suggest that inhibiting VHR could be beneficial in treating sepsis and septic shock. VHR belongs to the superfamily of protein tyrosine phosphatases (PTPs), a large class of enzymes that are notoriously difficult to target with small molecules. Fragment-based drug discovery (FBDD) has emerged as an effective strategy for generating potent ligands, even for challenging drug targets. Here, we present a fluorine NMR-based discovery platform for identifying fragments that bind to VHR. This platform encompasses automated library assembly, mixture formation, quantitative material transfer, fluorine NMR screening, and biophysical hit confirmation. We demonstrate that this streamlined, integrated screening workflow produces validated hits with diverse chemical matter and tangible structure-activity relationships (SAR). Crystal structures yielded detailed information on the fragment-protein interactions and provide a basis for future structurally enabled ligand optimization. Notably, we discovered novel ligand binding sites on VHR, distant from the conserved active site, facilitating the generation of selective VHR modulators. This fragment discovery platform can be applied to other PTPs and holds significant potential for identifying potent and selective ligands.

PubMed: 39959108
DOI: 10.1021/acsomega.4c10321

Experimental method

X-RAY DIFFRACTION (1.8 Å)